Interleukins and redox impairment in type 2 diabetes mellitus: mini-review and pilot study

References

• Fitipaldi H, McCarthy MI, Florez JC, et al. A global overview of precision medicine in type 2 diabetes. Diabetes. 2018;67(10):1911–1922.
   PubMed Web of Science ®Google Scholar
• Pan A, Wang Y, Talaei M, et al. Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation. 2015;132(19):1795–1804.
   PubMed Web of Science ®Google Scholar
• Minihane AM, Vinoy S, Russell WR, et al. Low-grade inflammation, diet composition and health: current research evidence and its translation. Br J Nutr. 2015;114(7):999–1012.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98.
   PubMed Web of Science ®Google Scholar
• Ungurianu A, Şeremet O, Gagniuc E, et al. Preclinical and clinical results regarding the effects of a plant-based antidiabetic formulation versus well established antidiabetic molecules. Pharmacol Res. 2019;150:104522.
   PubMed Web of Science ®Google Scholar
• Gradinaru D, Margina D, Borsa C, et al. Adiponectin: possible link between metabolic stress and oxidative stress in the elderly. Aging Clin Exp Res. 2017;29(4):621–629.
   PubMed Web of Science ®Google Scholar
• Sai Laxmi M, Prabhakar O. Inflammatory biomarkers as a part of diagnosis in diabetic peripheral neuropathy. J Diabetes Metab Disord. 2021;20(1):869–882.
   PubMed Web of Science ®Google Scholar
• Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–150.
   PubMed Web of Science ®Google Scholar
• Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance-a mini-review. Gerontology. 2009;55(4):379–386.
   PubMed Web of Science ®Google Scholar
• Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005;54(Suppl 2):S114–S24.
   PubMed Web of Science ®Google Scholar
• Ungurianu A, Zanfirescu A, Nițulescu G, et al. Vitamin E beyond its antioxidant label. Antioxidants (Basel). 2021;10(5):634.
   PubMedGoogle Scholar
• Margina D, et al. Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease. Food Chem Toxicol. 2020;143:111558.
   PubMed Web of Science ®Google Scholar
• Giulietti A, van Etten E, Overbergh L, et al. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract. 2007;77(1):47–57.
   PubMed Web of Science ®Google Scholar
• Agrawal NK, Kant S. Targeting inflammation in diabetes: newer therapeutic options. World J Diabetes. 2014;5(5):697–710.
   PubMedGoogle Scholar
• Domingueti CP, Dusse LMS, Carvalho M. D G, et al. Diabetes mellitus: the linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. J Diabetes Complications. 2016;30(4):738–745.
   PubMed Web of Science ®Google Scholar
• Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286–1292.
   PubMed Web of Science ®Google Scholar
• Wang X, Bao W, Liu J, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and Meta-analysis. Diabetes Care. 2013;36(1):166–175.
   PubMed Web of Science ®Google Scholar
• Saukkonen T, Mutt SJ, Jokelainen J, et al. Adipokines and inflammatory markers in elderly subjects with high risk of type 2 diabetes and cardiovascular disease. Sci Rep. 2018;8(1):12816.
   PubMed Web of Science ®Google Scholar
• Rivero-González A, M IE, Marín-Delgado C, et al. Cytokines in diabetes and diabetic complications. In: Locati M, Foti M, editors. Cytokine effector functions in tissues. London: Academic Press. 2017. p. 119–129.
   Google Scholar
• Teodoro JS, Nunes S, Rolo AP, et al. Therapeutic options targeting oxidative stress, mitochondrial dysfunction and inflammation to hinder the progression of vascular complications of diabetes. Front Physiol. 2018;9:1857.
   PubMed Web of Science ®Google Scholar
• Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13(6):465–476.
   PubMed Web of Science ®Google Scholar
• Everett BM, Donath MY, Pradhan AD, et al. Anti-Inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018;71(21):2392–2401.
   PubMed Web of Science ®Google Scholar
• Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin Chim Acta. 2012;413(15-16):1163–1170.
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132(6):2169–2180.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2010;17(4):314–321.
   PubMed Web of Science ®Google Scholar
• Kaneto H, Xu G, Fujii N, et al. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem. 2002;277(33):30010–30018.
   PubMed Web of Science ®Google Scholar
• McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia. 1999;42(2):128–138.
   PubMed Web of Science ®Google Scholar
• Feve B, Bastard JP. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(6):305–311.
   PubMed Web of Science ®Google Scholar
• Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433–442.
   PubMed Web of Science ®Google Scholar
• Glund S, Krook A. Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol (Oxf)). 2008;192(1):37–48.
   PubMed Web of Science ®Google Scholar
• Spranger J, Kroke A, MöHlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes. 2003;52(3):812–817., p.
   PubMed Web of Science ®Google Scholar
• Vozarova B, Fernández-Real J-M, Knowler WC, et al. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet. 2003;112(4):409–413.
   PubMed Web of Science ®Google Scholar
• Pradhan AD. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda K-h, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4(12):e8158.
   PubMed Web of Science ®Google Scholar
• Saxena A, Khosraviani S, Noel S, et al. Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine. 2015;74(1):27–34.
   PubMed Web of Science ®Google Scholar
• Ouyang W, Rutz S, Crellin NK, et al. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71–109.
   PubMed Web of Science ®Google Scholar
• Wang H, Wang L, Chi P-D, et al. High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma. Br J Cancer. 2016;114(4):463–468.
   PubMed Web of Science ®Google Scholar
• Goswami B, Rajappa M, Mallika V, et al. TNF-alpha/IL-10 ratio and C-reactive protein as markers of the inflammatory response in CAD-prone North Indian patients with acute myocardial infarction. Clin Chim Acta. 2009;408(1-2):14–18.
   PubMed Web of Science ®Google Scholar
• Heeschen C, Dimmeler S, Hamm CW, et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107(16):2109–2114.
   PubMed Web of Science ®Google Scholar
• Margina D, Ilie M, Gradinaru D. Quercetin and epigallocatechin gallate induce in vitro a dose-dependent stiffening and hyperpolarizing effect on the cell membrane of human mononuclear blood cells. Int J Mol Sci. 2012;13(4):4839–4859.
   PubMed Web of Science ®Google Scholar
• Tibuakuu M, Kamimura D, Kianoush S, et al. The association between cigarette smoking and inflammation: the genetic epidemiology network of arteriopathy (GENOA) study. PLoS One. 2017;12(9):e0184914.
   PubMed Web of Science ®Google Scholar
• Kianoush S, Yakoob MY, Al-Rifai M, et al. Associations of cigarette smoking with subclinical inflammation and atherosclerosis: ELSA-Brasil (The Brazilian Longitudinal Study of Adult Health). J Am Heart Assoc. 2017;6(6):e005088.
   PubMed Web of Science ®Google Scholar
• Pfutzner A, Schöndorf T, Hanefeld M, et al. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol. 2010;4(3):706–716.
   PubMedGoogle Scholar
• Xia M, Zhang C, Gu J, et al. Impact of C-reactive protein on long-term mortality in acute myocardial infarction patients with diabetes and those without. Clin Chim Acta. 2018;480:220–224.
   PubMed Web of Science ®Google Scholar
• Smidowicz A, Regula J. Effect of nutritional status and dietary patterns on human serum C-reactive protein and interleukin-6 concentrations. Adv Nutr. 2015;6(6):738–747.
   PubMed Web of Science ®Google Scholar
• Doupis J, Lyons TE, Wu S, et al. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009;94(6):2157–2163.
   PubMed Web of Science ®Google Scholar
• Uceyler N, Rogausch JP, Toyka KV, et al. Differential expression of cytokines in painful and painless neuropathies. Neurology. 2007;69(1):42–49.
   PubMed Web of Science ®Google Scholar
• Rexrode KM, Pradhan A, Manson JE, et al. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol. 2003;13(10):674–682.
   PubMed Web of Science ®Google Scholar
• Song J, Park DW, Moon S, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the sepsis-3 definitions. BMC Infect Dis. 2019;19(1):968.
   PubMed Web of Science ®Google Scholar
• Marti Arjona L, Moreno Camacho A. Prognostic value of interleukin-6 for death in patients with sepsis. Med Clin. 2017;149(11):507.
   PubMed Web of Science ®Google Scholar
• Satis H, Özger HS, Yıldız PA, et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19. Cytokine. 2021;137:155302.
   PubMed Web of Science ®Google Scholar
• Xu J, Ye Y, Zhang H, et al. Diagnostic and prognostic value of serum interleukin-6 in colorectal cancer. Medicine, 2016;95(2):e2502.
   PubMed Web of Science ®Google Scholar
• Yang H, Han Y, Wu L, et al. Diagnostic and prognostic value of serum interleukin‑16 in patients with gastric cancer. Mol Med Rep. 2017;16(6):9143–9148.
   PubMed Web of Science ®Google Scholar
• Wang X-F, Zhu Y-T, Wang J-J, et al. The prognostic value of interleukin-17 in lung cancer: a systematic review with Meta-analysis based on Chinese patients. PLoS One. 2017;12(9):e0185168.
   PubMed Web of Science ®Google Scholar
• Cavus B, et al. Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma. Exp Oncol. 2020;42(3):208–214.
   PubMedGoogle Scholar
• Kobayashi T, Baghdadi M, Han N, et al. Prognostic value of IL-34 in colorectal cancer patients. Immunol Med. 2019;42(4):169–175.
   PubMedGoogle Scholar
• Bustamante A, Sobrino T, Giralt D, et al. Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and Meta-analysis. J Neuroimmunol. 2014;274(1–2):215–224.
   PubMed Web of Science ®Google Scholar
• Dai Z, Jiao Y, Fan Q, et al. Homocysteine, interleukin-1beta, and fasting blood glucose levels as prognostic markers for diabetes mellitus complicated with cerebral infarction and correlated with carotid intima-media thickness. Exp Ther Med. 2019;19(2):1167–1174.
   PubMed Web of Science ®Google Scholar
• Liu T, Deng J-M, Liu Y-L, et al. The relationship between gestational diabetes mellitus and interleukin 1beta gene polymorphisms in southwest of China. Medicine. 2020;99(43):e22679.
   PubMed Web of Science ®Google Scholar
• Ganesan SM, Joshi V, Fellows M, et al. A tale of two risks: smoking, diabetes and the subgingival microbiome. Isme J. 2017;11(9):2075–2089.
   PubMed Web of Science ®Google Scholar
• Awadalla H, Almobarak AO, Ahmed MH. Prevalence of smoking in Sudanese individuals with diabetes and associated complications: population-based study. Diabetes Metab Syndr. 2018;12(5):749–751.
   PubMed Web of Science ®Google Scholar
• Xuan Y, Gào X, Anusruti A, et al. Association of serum markers of oxidative stress with incident major cardiovascular events, cancer incidence, and all-cause mortality in type 2 diabetes patients: pooled results from two cohort studies. Diabetes Care. 2019;42(8):1436–1445.
   PubMed Web of Science ®Google Scholar
• Malik A, Morya RK, Saha S, et al. Oxidative stress and inflammatory markers in type 2 diabetic patients. Eur J Clin Invest. 2020;50(6):e13238.
   PubMed Web of Science ®Google Scholar
• Rehman K, Akash MSH. Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they interlinked? J Cell Biochem. 2017;118(11):3577–3585.
   PubMed Web of Science ®Google Scholar
• Cournot M, Burillo E, Saulnier PJ, et al. Circulating concentrations of redox biomarkers do not improve the prediction of adverse cardiovascular events in patients with type 2 diabetes mellitus. J Am Heart Assoc. 2018;7(5):e007397.
   PubMed Web of Science ®Google Scholar
• von Scholten BJ, Reinhard H, Hansen TW, et al. Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria. J Diabetes Complications. 2016;30(2):248–255.
   PubMed Web of Science ®Google Scholar
• Luc K, Schramm-Luc A, Guzik TJ, et al. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019;70(6).
   PubMed Web of Science ®Google Scholar
• Odegaard AO, Jacobs DR, Sanchez OA, et al. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. 2016;15(1):51.
   PubMed Web of Science ®Google Scholar
• Kahleova H, Matoulek M, Malinska H, et al. Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with type 2 diabetes. Diabet Med. 2011;28(5):549–559.
   PubMed Web of Science ®Google Scholar
• Bouhajja H, Kacem FH, Abdelhedi R, et al. Potential predictive role of lipid peroxidation markers for type 2 diabetes in the adult Tunisian population. Can J Diabetes. 2018;42(3):263–271.
   PubMed Web of Science ®Google Scholar
• Mallard AR, Hollekim-Strand SM, Ingul CB, et al. High day-to-day and diurnal variability of oxidative stress and inflammation biomarkers in people with type 2 diabetes mellitus and healthy individuals. Redox Rep. 2020;25(1):64–69.
   PubMed Web of Science ®Google Scholar
• Menzel A, Samouda H, Dohet F, et al. Common and novel markers for measuring inflammation and oxidative stress ex vivo in research and clinical practice-which to use regarding disease outcomes? Antioxidants (Basel). 2021;10(3):414.
   PubMedGoogle Scholar
• Shiels MS, Katki HA, Freedman ND, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014;106(11):dju294.
   PubMedGoogle Scholar
• Asthana A, Johnson HM, Piper ME, et al. Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokers. Am Heart J. 2010;160(3):458–463.
   PubMed Web of Science ®Google Scholar
• Joseph A, Hecht S, Murphy S, et al. Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial. Nicotine Tobacco Res. 2008;10(3):471–481.
   PubMed Web of Science ®Google Scholar
• Kleiner G, Marcuzzi A, Zanin V, et al. Cytokine levels in the serum of healthy subjects. Mediators Inflamm. 2013;2013:434010.
   PubMed Web of Science ®Google Scholar
• American Diabetes, A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S14–S31.
   PubMed Web of Science ®Google Scholar
• Gradinaru D, Khaddour H, Margina D, et al. Insulin-leptin axis, cardiometabolic risk and oxidative stress in elderly with metabolic syndrome. Exp Clin Endocrinol Diabetes. 2018;126(07):445–452.
   Web of Science ®Google Scholar
• Ungurianu A, Margină D, Grădinaru D, et al. Lipoprotein redox status evaluation as a marker of cardiovascular disease risk in patients with inflammatory disease. Mol Med Rep. 2017;15(1):256–262.
   PubMed Web of Science ®Google Scholar
• Ungurianu A, Șeremet O, Grădinaru D, et al. Spectrophotometric versus spectrofluorometric assessment in the study of the relationships between lipid peroxidation and metabolic dysregulation. Chem Biol Drug Des. 2019;93(6):1026–1035.
   PubMed Web of Science ®Google Scholar
• Klafke JZ, Porto FG, Batista R, et al. Association between hypertriglyceridemia and protein oxidation and proinflammatory markers in normocholesterolemic and hypercholesterolemic individuals. Clin Chim Acta. 2015;448:50–57.
   PubMed Web of Science ®Google Scholar
• Shu Y, Chen Y, Luo H, et al. The roles of IL-10 gene polymorphisms in diabetes mellitus and their associated complications: a meta-analysis. Horm Metab Res. 2018;50(11):811–815.
   PubMed Web of Science ®Google Scholar
• Rodrigues KF, Pietrani NT, Bosco AA, et al. IL-6, TNF-α, and IL-10 levels/polymorphisms and their association with type 2 diabetes mellitus and obesity in Brazilian individuals. Arch Endocrinol Metab. 2017;61(5):438–446.
   PubMed Web of Science ®Google Scholar
• Dwivedi S, Goel A, Khattri S, et al. Genetic variability at promoters of IL-18 (pro-) and IL-10 (anti-) inflammatory gene affects susceptibility and their circulating serum levels: an explorative study of prostate cancer patients in North indian populations. Cytokine. 2015;74(1):117–122.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457.
   PubMed Web of Science ®Google Scholar
• Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018;26(3):685–698.
   PubMed Web of Science ®Google Scholar
• Jaganathan R, Ravindran R, Dhanasekaran S. Emerging role of adipocytokines in type 2 diabetes as mediators of insulin resistance and cardiovascular disease. Can J Diabetes. 2018;42(4):446–456 e1.
   PubMed Web of Science ®Google Scholar
• Lontchi-Yimagou E, Sobngwi E, Matsha TE, et al. Diabetes mellitus and inflammation. Curr Diab Rep. 2013;13(3):435–444.
   PubMed Web of Science ®Google Scholar
• Wensveen FM, Valentić S, Šestan M, et al. The "big bang" in obese fat: events initiating obesity-induced adipose tissue inflammation. Eur J Immunol. 2015;45(9):2446–2456.
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111–1119.
   PubMed Web of Science ®Google Scholar
• Lin Y, Berg AH, Iyengar P, et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem. 2005;280(6):4617–4626.
   PubMed Web of Science ®Google Scholar
• Goldfine AB, Shoelson SE. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest. 2017;127(1):83–93.
   PubMed Web of Science ®Google Scholar
• Richardson VR, Smith KA, Carter AM. Adipose tissue inflammation: feeding the development of type 2 diabetes mellitus. Immunobiology. 2013;218(12):1497–1504.
   PubMed Web of Science ®Google Scholar
• Zanfirescu A, Ungurianu A, Tsatsakis AM, et al. A review of the alleged health hazards of monosodium glutamate. Compr Rev Food Sci Food Saf. 2019;18(4):1111–1134.
   PubMed Web of Science ®Google Scholar
• Matthews VB, Allen TL, Risis S, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia. 2010;53(11):2431–2441.
   PubMed Web of Science ®Google Scholar
• Yusof MY, Emery P. Targeting interleukin-6 in rheumatoid arthritis. Drugs. 2013;73(4):341–356.
   PubMed Web of Science ®Google Scholar
• Strang AC, Bisoendial RJ, Kootte RS, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229(1):174–181.
   PubMed Web of Science ®Google Scholar
• Kraakman MJ, Kammoun HL, Allen TL, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015;21(3):403–416.
   PubMed Web of Science ®Google Scholar
• Morteza A, Nakhjavani M, Ghadiri-Anari A, et al. Serum interleukin-1 and interleukin-6 are correlated neither with oxidized low density lipoprotein, nor with low-grade inflammation in patients with type 2 diabetes. Eur Cytokine Netw. 2011;22(2):107–112.
   PubMed Web of Science ®Google Scholar
• Likidlilid A, Patchanans N, Peerapatdit T, et al. Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients. J Med Assoc Thai. 2010;93(6):682–693.
   PubMedGoogle Scholar
• van Exel E, Gussekloo J, de Craen AJM, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the leiden 85-plus study. Diabetes. 2002;51(4):1088–1092.
   PubMed Web of Science ®Google Scholar
• Gotoh K, Fujiwara K, Anai M, et al. Role of spleen-derived IL-10 in prevention of systemic low-grade inflammation by obesity [review]. Endocr J. 2017;64(4):375–378.
   PubMed Web of Science ®Google Scholar
• Besler C, Luscher TF, Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med. 2012;4(4):251–268.
   PubMed Web of Science ®Google Scholar
• Feigerlova E, Battaglia-Hsu SF. IL-6 signaling in diabetic nephropathy: from pathophysiology to therapeutic perspectives. Cytokine Growth Factor Rev. 2017;37:57–65.
   PubMed Web of Science ®Google Scholar
• Gustavsson C, Agardh CD, Agardh E. Profile of intraocular tumour necrosis factor-alpha and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol. 2013;91(5):445–452.
   PubMed Web of Science ®Google Scholar
• Dong N, Xu B, Wang B, et al. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19:1734–1746.
   PubMed Web of Science ®Google Scholar
• Izuora KE, Chase HP, Jackson WE, et al. Inflammatory markers and diabetic retinopathy in type 1 diabetes. Diabetes Care. 2005;28(3):714–715.
   PubMed Web of Science ®Google Scholar
• Umapathy D, Dornadula S, Krishnamoorthy E, et al. YKL-40: a biomarker for early nephropathy in type 2 diabetic patients and its association with inflammatory cytokines. Immunobiology. 2018;223(11):718–727.
   PubMed Web of Science ®Google Scholar
• Sangoi MB, de Carvalho JAM, Tatsch E, et al. Urinary inflammatory cytokines as indicators of kidney damage in type 2 diabetic patients. Clin Chim Acta. 2016;460:178–183.
   PubMed Web of Science ®Google Scholar
• Dalla Vestra M, Mussap M, Gallina P, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. JASN. 2005;16(3 suppl 1):S78–S82.
   Web of Science ®Google Scholar
• Marioni RE, Strachan MWJ, Reynolds RM, et al. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes. 2010;59(3):710–713.
   PubMed Web of Science ®Google Scholar
• Sabouri M, Hatami E, Pournemati P, et al. Inflammatory, antioxidant and glycemic status to different mode of high-intensity training in type 2 diabetes mellitus. Mol Biol Rep. 2021;48(6):5291–5304.
   PubMed Web of Science ®Google Scholar